Ibdenc

12/03/2026

✅Editorial Recommendations – March 2026
This month, IBD-ENC highlights five important publications from leading journals, showcasing key advancements in inflammatory bowel disease (IBD) research and management.

📄A systematic review evaluates the effectiveness and safety of JAK inhibitors in acute severe ulcerative colitis

📄The SHINE-1 trial investigates the efficacy and safety of mirikizumab in paediatric ulcerative colitis

📄A 10-year follow-up of the LIR!C trial compares ileocaecal resection versus infliximab for ileal Crohn’s disease

📄An IOIBD consensus paper explores the role of artificial intelligence in assessing endoscopic and histologic endpoints in IBD trials

📄A meta-analysis reviews the potential role of the Mediterranean diet in the treatment of IBD

Together, these studies highlight progress in therapeutics, clinical trial methodology, and supportive lifestyle strategies in IBD care.

👉 Explore more at: www.ibdenc.org

25/02/2026

Longer Steroid Taper Improves Remission in Moderate–Severe Ulcerative Colitis.
A randomized trial shows that extending oral steroid tapering to 10 weeks significantly increases steroid-free remission at six months compared with a 6-week taper, with similar safety outcomes.



Know more:

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial.Thi...

17/02/2026

🚨 Registrations Open - Limited Seats!
Link: https://forms.office.com/r/QLiLYhca26

Upgrade your clinical expertise with the AIG IUS Preceptorship in IBD 2026 at AIG Hospitals - a hybrid learning program designed to help you master intestinal ultrasound in IBD.

Learn from global experts: Kerri Novak || Shintaro Sagami

-Foundations of IUS
-IUS in Crohn’s Disease & Ulcerative Colitis
-Multimodal diagnostic approach
-Case-based discussions + practical insights

📅 Batch 1: March 23–28
📅 Batch 2: June 22–27

Seats are limited - secure yours today!

👉 Register now: https://forms.office.com/r/QLiLYhca26

12/02/2026

Early Vedolizumab Use Improves Remission and Safety Outcomes in Crohn’s Disease.
Starting vedolizumab earlier in Crohn’s disease may lead to better remission rates and fewer serious adverse events. A phase 4 European study shows significantly improved outcomes in biologic-naive patients treated within 2 years of diagnosis.
See more: https://youtu.be/Axt2yuFhdyM

Vedolizumab in Crohn's, earlier the better:Vedolizumab is effective for Crohn’s disease, but its benefits in early disease are not well defined. This phase 4...

11/02/2026

Editorial Recommendations – February 2026

This month, IBD-ENC highlights five impactful publications from leading journals, bringing forward important developments in inflammatory bowel disease (IBD) care.

1. A randomized trial evaluates long versus short steroid tapering strategies in moderate to severe ulcerative colitis

2. Exclusive enteral nutrition is compared with partial enteral nutrition for maintaining drug-free remission in paediatric Crohn’s disease

3. New data examine appendicectomy versus switching to a JAK inhibitor after biologic failure in ulcerative colitis

4. Emerging evidence identifies extrachromosomal circular DNA as a potential biomarker for IBD type and activity

5. An international expert consensus defines diagnosis and management strategies for upper gastrointestinal Crohn’s disease

Together, these studies provide timely insights to support evidence-based IBD practice.

👉 Explore more at: www.ibdenc.org

27/01/2026

🔰Watch Now: https://youtu.be/_8TiAeSbVB4
Emerging evidence shows the Oral Microbiome plays a critical role in inflammatory bowel disease. This editorial explores new mechanisms, systemic implications, and how this science may reshape best-practice care for IBD.

The oral microbiome is more than a dental concern - it plays a critical role in systemic inflammation and gastrointestinal disease. This video explores new e...

13/01/2026

Moments from Ibdenc – The Madras Consensus, bringing together experts to align perspectives on advanced IBD management.
The meeting also marked the launch of The IBDENC Journal, supporting continued scientific dialogue and collaboration.

Nalini Raghunathan Dhanush Mekala Dr. Sushant Kumar Sethi Dr. Chalapathi Rao, Liver and Gastro

09/01/2026

🔰Editorial Recommendations - January 2026
This month, IBD-ENC presents five carefully curated articles from high-impact journals, offering key insights into the evolving management of inflammatory bowel disease (IBD).
1) Evidence supports early use of vedolizumab in Crohn’s disease, showing improved remission and safety outcomes
2) A novel oral bispecific antibody (SOR102) demonstrates promising early efficacy in ulcerative colitis
3) New multinational Asian data enhance understanding of PSC-IBD prevalence and outcomes
4) Long-term registry data reveal a declining risk of colorectal cancer after low-grade dysplasia in IBD
5) A meta-analysis questions the continued role of 5-ASA after escalation to advanced therapies

Together, these studies provide a concise snapshot of clinically relevant advances shaping contemporary IBD practice.

👉 Explore more at: www.ibdenc.org

03/01/2026

🔰Watch Now: https://youtu.be/rrXy061EDIE
Creeping fat isn’t just a bystander in Crohn’s disease.
New research highlights how mesenteric adipose tissue and gut microbiota influence inflammation, barrier function, and FMT outcomes. Watch the video.

Inflammatory bowel disease (IBD), particularly Crohn’s disease (CD), is increasingly recognized as a disorder involving not only the gut but also the mesente...

31/12/2025

Welcoming 2026 with a significant milestone for the IBD community 🎉

IBD-ENC (Emerging Nations’ Consortium) proudly launches the IBDENC Journal - a peer-reviewed, open-access platform advancing region-relevant IBD evidence from emerging nations.

Here’s to a year of collaboration, research, and global impact.

More at www.ibdenc.org

25/12/2025

✨ Season’s Greetings from IBDENC ✨

This festive season, we celebrate hope, progress, and purpose.
As we welcome 2026, we are proud to announce a landmark milestone —
📘 The launch of the IBDENC Journal – Rise Edition (January 2026).

A peer-reviewed, open-access platform dedicated to advancing region-relevant IBD evidence from emerging nations, empowering better care for patients worldwide.

🎄 Wishing our global IBD community a Merry Christmas and a Happy New Year —
bringing you the gift that matters most: evidence that empowers care.

🌐 www.ibdenc.org

17/12/2025

🔰IBD-ENC Journal Recommendation - Multi-Omics Analysis of Ileal Mucosa and Mesentery Before and After Ileocecal Resection in Crohn's Disease.
👉Crohn’s disease (CD) is a chronic inflammatory condition affecting any part of the gastrointestinal tract, with the ileocecal region often being the initial site of involvement. This study explored the microbial and metabolic impacts of ileocecal resection in early CD to better understand its therapeutic value. Using 16S rRNA sequencing and LC-MS/MS, researchers analyzed 68 samples of terminal ileal mucosa and mesentery from 34 CD patients before and after surgery. Results demonstrated improved microbial diversity and metabolic health in both tissues post-resection, alongside distinct spatial changes in microbial and metabolite profiles. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis further revealed key metabolic shifts associated with remission. These findings highlight ileocecal resection as an effective intervention that not only reduces inflammation but also restores microbial homeostasis, providing multi-omics evidence for its role in guiding precision, microbiome-informed treatment strategies for Crohn’s disease.

This IBD-ENC journal review discusses a high-impact research article published in the United European Gastroenterology (UEG) Journal, available on the wiley ...